A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes

Hackensack Meridian Health13 enrolled

Overview

This is a prospective, single arm, open-label, single-center pilot study to assess the safety, feasibility, and efficacy of Stem Cell Educator therapy for the treatment of patients with Type 1 Diabetes.

Our previous work demonstrated that human cord blood-derived multipotent stem cells (CB-SCs) are a unique type of stem cell identified from human cord blood, distinct from other stem cell types including hematopoietic stem cells (HSCs), and mesenchymal stem cells (MSCs). The stem cells and harnessed some of their unique properties with Stem Cell Educator therapy by using CB-SCs in a closed-loop system that circulates a patient's blood through a blood cell separator, briefly co-cultures the patient's lymphocytes with adherent CB-SCs in vitro, and returns the "educated" lymphocytes (but not the CB-SCs) to the patient's circulation . This treatment leads to global immune modulations and immune balance as demonstrated by clinical data and animal studies. The Stem Cell Educator therapy may revolutionize the clinical treatment of diabetes and other immune-related diseases through CB-SCs' immune education and induction of immune balance, without the safety and ethical concerns associated with conventional stem cell-based approaches

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetes Mellitus Type 1

Interventions

Stem Cell Educator TherapyBIOLOGICAL

Patients will receive apheresis and then have their own blood returned to them with the "educated" lymphocytes

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients \>/=18 years * Must have a diagnosis of type 1 diabetes mellitus based on the 2015 American Diabetes Association criteria for the Clarification and Diagnosis of diabetes * Must have a blood test confirming the presence of at least one autoantibody to pancreatic islet cells (IAA, IA2, GAD 65, ZnT8) * Fasting C-peptide level \> 0.3 ng/ml * Adequate venous access for apheresis * Ability to provide informed consent * Must agree to comply with all study requirements and be willing to complete all study visits Exclusion Criteria: * AST or ALT 2 \> x upper limit of normal. * Creatinine \> 2.0 mg/dl. * Known coronary artery disease or EKG suggestive of coronary artery disease unless cardiac clearance for apheresis is obtained from a cardiologist. * Known active infection * Pregnancy or breastfeeding mothers * Use of immunosuppressive medication within one month of enrollment including but not limited to prednisone, cyclosporine, tacrolimus, sirolimus, and chemotherapy. * Presence of any other autoimmune diseases (lupus, rheumatoid arthritis, scleroderma, etc.) * Anticoagulation other than ASA. * Hemoglobin \< 10 g/dl or platelets \< 100 k/ml * Is unable or unwilling to provide informed consent * Presence of any other physical or psychological medical condition that, in the opinion of the investigator, would preclude participation

Locations (1)

Hackensack University Medical Center - John Theurer Cancer Center

Hackensack, New Jersey, United States

Outcomes

Primary Outcomes

Number of Participants With Treatment Related Adverse Events

The primary study endpoint will be the occurrence of treatment-related adverse effects. Adverse events that occur during therapy (especially those that necessitate temporary or permanent discontinuation of therapy) and over the 12-month follow-up period will be assessed.

Time frame: 12 months

Secondary Outcomes

Number of Patients Unable to Complete Therapy

Number of patients who were unable to complete SCE Therapy.

Time frame: One week

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.